New registry aims to unlock secrets of rare kidney cancer
NCT ID NCT03630536
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study created a registry of 28 patients with TFE renal cell carcinoma, a rare kidney cancer. Researchers collected medical data, tumor samples, and images to better understand the disease. The goal is to use this information to guide future research and develop more effective treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this registry could provide insights that help develop better treatments for TFE renal cell carcinoma.
- What could go wrong
- This is an observational registry, not a treatment trial. It does not test any therapy directly, so benefits for patients are indirect and long-term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict who needs extra therapy after kidney cancer surgery?
- Can a Two-Drug combo outsmart advanced cancers?
- Can a rapid drug switch outsmart advanced kidney cancer?
- Can a new nucleotide analogue boost cancer treatment?
- Can a blast of radiation make immunotherapy work better against kidney cancer?
- Can reprogrammed immune cells take on hard-to-treat kidney cancer?